Cannabis Law Report

JULY 1, 2021

The Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School is engaged in a three-year initiative to examine the ethical, legal, and social implications of psychedelics research, commerce, and therapeutics. Access to Psychedelic Therapies and Equity in Emerging Psychedelics Industries. Background.

Law 59

Law Policy Research and Development Clinical Trials 59

Cannabis Law Report

SEPTEMBER 10, 2021

This exciting partnership between these innovative startups aims to advance patient access to psychedelic treatments in Europe, and improve the quality of the psychedelic medicines produced in Europe. We look forward to working closely with the Clerkenwell Health team to advance our psychedelic drug programs through clinical trials.”.

Research and Development 104

Research and Development Clinical Trials Therapy Environment 104

Cannabis Law Report

JUNE 24, 2022

Scutari’s proposed “Psilocybin Behavioral Health Access and Services Act” represents a bold development in the psychedelics reform movement that’s rapidly spread in state legislatures and through citizen-led initiatives throughout the country in recent years. Full story at.

Clinical Trials 52

Clinical Trials Legalization Research and Development Therapy 52

Cannabis Law Report

FEBRUARY 10, 2022

Despite Petitioners’ noble cause, the case turned on a technicality after the Court determined that the DEA’s letter stating that such psilocybin treatment was not allowed, the document that prompted the lawsuit, was not a “final” decision of the Attorney General that the Court had jurisdiction to review. Background. Psilocybin. The RTT Act.

DEA 52

DEA Clinical Trials Policy Research and Development 52

MMJ Recs

DECEMBER 17, 2023

Enacted in 2015, the program was designed to provide a narrow avenue for patients suffering from qualifying conditions to access low-THC cannabis under the supervision of qualified healthcare professionals. They also have the right to obtain their medication from licensed dispensaries that adhere to state regulations.

Law 52

Law Dispensary Clinical Trials Programs 52

Canna Law Blog

NOVEMBER 6, 2021

Despite overwhelming evidence that psilocybin is misclassified, this barrier restricts research, stifles competition and innovation, and inhibits access. But only if it is made affordable and accessible. Instead, qualifying evidence may come from adequate and well-controlled clinical trials. For two decades, U.S.

Clinical Trials 98

Clinical Trials DEA Research and Development Therapy 98

Cannabis Law Report

APRIL 21, 2022

Commercialization & Patient Access · Any City, Any State, California. MAPS PBC is pioneering new forms of mental health care, beginning with the development of MDMA-assisted therapy as an FDA-approved treatment for post-traumatic stress disorder (PTSD). About MAPS Public Benefit Corporation (MAPS PBC). Executive Summary.

Advocacy 52

Advocacy Therapy Clinical Trials Environment 52

Project CBD

FEBRUARY 28, 2023

5 In June 2018, the FDA approved Epidiolex® (GW Pharmaceuticals; Cambridge, UK), the first FDA-approved pharmaceutical drug to contain a “purified drug substance [CBD] derived from marijuana,” for the treatment of seizures associated with two rare epilepsy disorders. Accessed July 25, 2021. Accessed October 17, 2022.

CBD 144

CBD Seed-To-Sale Food Access 144

Cannabis Law Report

OCTOBER 4, 2021

A multitude of recent clinical trials shows the clear promise of psilocybin for this population suffering from these debilitating conditions. Accordingly, it cannot be prescribed by a physician and it is not legally accessible to those who might benefit from it as a therapeutic treatment.

Therapy 52

Therapy Patients Law Clinical Trials 52

Cannabis Law Report

JUNE 3, 2022

COMPASS Pathways is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. Experience drafting corporate agreements and policies.

Legalization 59

Legalization Clinical Trials Compliance Compliance 59

MMJ Recs

DECEMBER 22, 2023

The AIDS epidemic in the 1980s brought attention to the potential benefits of marijuana in alleviating symptoms such as nausea and appetite loss associated with the disease and its treatment. These campaigns focus on dispelling myths, highlighting success stories, and educating the public about the science behind cannabis-based treatments.

Marijuana 52

Marijuana Chronic Pain Advocacy Research and Development 52

Cannabis Law Report

JANUARY 12, 2022

Today, Maya (Maya PBC) and the National Psychedelics Association (NPA) announced their partnership in support of the implementation of Oregon’s Measure 109, the first state-approved policy to allow the regulated use of psilocybin products in a facilitated setting.

Research and Development 52

Research and Development Therapy Safety Clinical Trials 52

Otherside Farms

JANUARY 25, 2019

Smith was diagnosed with inoperable liver cancer in 2009 and sought treatment from the internationally known Cedars-Sinai in L.A. Smith’s cancer was in remission until just recently, but now he is scheduled to undergo radiation treatments in a few days.

Patients 76

Patients Clinical Trials Marijuana Policy 76

Cannabis Law Report

NOVEMBER 19, 2021

MAPS PBC is pioneering a new form of mental health care, beginning with the development of MDMA-assisted therapy as an FDA-approved treatment for PTSD. MDMA-assisted therapy is a new paradigm in the treatment of mental health, combining a medicine with psychotherapy to address the root causes of PTSD. Key Responsibilities.

Research and Development 52

Research and Development Clinical Trials Therapy Pharmaceutical 52

Cannabis Law Report

MARCH 1, 2022

COMPASS Pathways is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. Experience drafting corporate agreements and policies.

Legalization 52

Legalization Clinical Trials Compliance Compliance 52

Cannabis Law Report

OCTOBER 2, 2021

COMPASS Pathways is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. Experience drafting corporate agreements and policies.

Legalization 52

Legalization Clinical Trials Compliance Compliance 52

Project CBD

NOVEMBER 11, 2023

And then cannabis has unique effects for a wide range of conditions, everything from the treatment of pain, treatment of asthma, treatment of immune conditions. We rate levels of evidence, and a high level may be a controlled randomized clinical trial (RCT), but there are also observational studies.

Medicine 301

Medicine Research and Development Pharmaceutical Cannabis 301

Cannabis Law Report

NOVEMBER 29, 2019

Different legislation across EU countries on prescribing cannabis-based medicines can hinder patients’ access to their treatment when they travel abroad, EUMCA said. Our main priority is informing national and EU institutions about the opportunity that this treatment is offering,” said Sita Schubert, secretary general of EUMCA.

Medicine 59

Medicine Clinical Trials Treatment Access 59

Cannabis Law Report

AUGUST 7, 2022

In recent years, as more clinical trial results show that psychedelics can be used in conjunction with therapy to treat illnesses like depression and post-traumatic stress disorder, legislators pushed to make certain substances available in certain settings. Psychedelic Alpha Policy Map. Where Laws Are Changing.

Law 74

Law Research and Development Therapy Treatment 74

Cannabis Law Report

APRIL 8, 2022

This year, we are completing the second Phase 3 clinical trial of MDMA-assisted therapy for PTSD , the final stage prior to requesting FDA approval for a new prescription treatment to help heal trauma. For over three decades, we’ve been working to achieve mass mental health throughout the United States, Canada, and Europe.

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

Cannabis Law Report

MAY 29, 2022

Widespread approval for psychedelic treatments remains unlikely, but the tide is slowly turning. In 2019, FDA approved Spravato (esketamine) nasal spray for treatment of depression in adults. [8] Clinical Trials and Human Subject Protections. For the regulated community, this is a trend worth watching.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Cannabis Law Report

MARCH 29, 2022

Former Moderna Vice President and Managing Director for North America recruited to prepare MAPS PBC for patient access and commercialization of the first psychedelic-assisted therapy anticipated to be approved by the FDA. has joined MAPS PBC as Head of Market Access. Amy Emerson , CEO, MAPS PBC. Michael Mullette , COO, MAPS PBC.

Therapy 52

Therapy Pharmaceutical Clinical Trials Access 52

Cannabis Law Report

FEBRUARY 28, 2022

Clinical trials are producing promising results, creating enthusiasm for commercializing and patenting psychedelics. Importantly, control of psychedelics by a small number of companies may stifle innovation and reduce access to these therapies. Mitchell et al., Divito & Robert F. Psychiatry May Never Be the Same , N.Y.

Research and Development 52

Research and Development Therapy Law Clinical Trials 52

Veriheal

MAY 12, 2021

The relationship between cannabis and cancer has long been at the forefront of research regarding its medical efficacy, mainly for legalization and treatment purposes. However, cannabis use amongst those with cancer is poorly understood, at least according to a team of researchers.

Patients 98

Patients Consumption Clinical Trials Education 98

Veriheal

MARCH 23, 2023

The people of Japan, a country renowned for its sushi cuisine scene, iconic Mount Fuji, and eye-catching cherry blossom trees, may soon have access to legal medicinal marijuana for intractable diseases. However, ever-evolving cannabis regulations in other Asian countries like Thailand have inspired lawmakers to adopt policy change in Japan.

Legalization 66

Legalization Marijuana Clinical Trials Seed-To-Sale 66

SpeedWeed

MARCH 18, 2021

Preliminary results from a long-awaited study indicate that cannabis appears to be a safe and well-tolerated treatment for patients managing post-traumatic stress disorder (PTSD), although researchers did not find strong signals of effectiveness. for the production of cannabis used in federally-regulated clinical trials.

Clinical Trials 40

Clinical Trials THC Strains Cannabis 40

Canna Law Blog

MARCH 4, 2020

From 2015 to 2018, the number of clinics increased from 60 to 300; that number is undoubtedly higher today. People are increasingly using ketamine for ailments that resist treatment through traditional pharmaceutical drugs. That access would be available under the auspices of having a chronic, untreatable mood disorder.

Therapy 89

Therapy Legalization Chronic Pain DEA 89

CannaMD

MARCH 8, 2021

1455 covers three major themes: medical marijuana advertising, THC potency/access to high-THC products, and administrative issues. Prohibiting a medical marijuana treatment center from dispensing marijuana that exceeds a certain potency of tetrahydrocannabinol [p. Food & Drug Association’s role in H.B. Florida H.B.

THC 116

THC Research and Development Treatment Patients 116

Cannabis Law Report

JANUARY 14, 2020

CLICK IMAGE TO ACCESS COMMITTEE INFO PAGE. Senior Policy Advisor, Diversion Control Division. Amidst growing evidence that marijuana can be used to effectively treat post-traumatic stress disorder , this bill from California Democrat Barbara Lee focuses on greatly expanding access to medical marijuana for veterans. Legislation.

Clinical Trials 69

Clinical Trials Programs Access DEA 69

Cannabis Law Report

JULY 14, 2021

(“ImmunoFlex” ), today announced that it has completed and analyzed its clinical trial of 21 patients, aged 60 to 70 years. ImmunoFlex’s believes that the immune system changes observed in this clinical study are beneficial changes with the potential to improve immune system competence. Karl Kottmeier” President.

Research and Development 105

Research and Development Clinical Trials Events Treatment 105

Cannabis Law Report

SEPTEMBER 14, 2021

13, 2021 /PRNewswire-PRWeb/ — A host of scientific research and clinical trials around the world are affirming the remarkable effectiveness of psilocybin, the principal psychoactive component of “magic mushrooms,” in the treatment of a variety of medical conditions, including depression, anxiety, addiction, and PTSD.

Clinical Trials 52

Clinical Trials Events Medicine Therapy 52

Cannabis Law Report

JUNE 1, 2021

Steve Barbera to Vice President, Market Access. Steve Barbera is an accomplished cross-functional leader in the healthcare industry, with over 20 years of experience in the development and implementation of complex market access strategies including health policy, pricing and reimbursement, contracts and coding. Sesen Bio, Inc.

Research and Development 66

Research and Development Treatment Pharmaceutical Patients 66

Cannabis Law Report

JUNE 9, 2022

We understand the number of people who will need medical treatment due to this exposure. The bill would expand patients’ access to the necessary treatment for more than 50 conditions, including cancer and post-traumatic stress disorder (PTSD), neurological diseases, and chronic pain of neuropathic origin.

Seed-To-Sale 52

Seed-To-Sale Legalization Cultivation Medicine 52

Cannabis Law Report

APRIL 10, 2019

MP Philippa Whitford (representing Central Ayrshire ), a doctor, called for more support for clinical trials so that doctors will be more willing to prescribe medical cannabis products: “That is quite scary for doctors, particularly as if it is an unlicensed drug, they have to sign a form to say that they accept personal liability.

Clinical Trials 51

Clinical Trials Epilepsy Medicine Research and Development 51

The Cannigma

MAY 7, 2021

The Cannabis Enigma podcast is a co-production of The Cannigma and Americans for Safe Access. You’ve had this conversation in the US for over 20 years in some states so it’s not as if suddenly overnight, people have woken up to the discussion of cannabis and cannabis legalization and cannabis access. Music by Desca.

Supply Chain 120

Supply Chain Patients Access Hemp 120

Cannabis Law Report

JULY 15, 2019

Law 33/2018 set the framework for the regulation of the use of cannabis-based medicinal products, preparations and substances that would effectively allow Portuguese patients to access medical cannabis What really has changed during the last year? The hardest part has already been done.

Medicine 40

Medicine Clinical Trials Patients Access 40

The Cannigma

JUNE 15, 2021

The first clinical research done on CBD as a potential treatment for epilepsy was in 1980, but the information gleaned didn’t make its way to the public eye until decades later. CBG, however, also has some medicinal potential that CBD doesn’t, for instance as a treatment for hypertension and insulin resistance. Shutterstock).

CBD 122

CBD Research and Development Epilepsy Extraction 122